Clinical Trial Update: COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating COM701 in combination with BMS-986207 and nivolumab in adults with advanced solid tumors, including endometrial neoplasms…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms
• Head and Neck Cancer
• Ovarian Cancer

Drugs mentioned

• BMS-986207
• COM701
• nivolumab (nivolumab)

Snippet

Sponsor: Compugen Ltd | Conditions: Endometrial Neoplasms, Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED